Navigation Links
GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging

Lamictal, an antiepileptic drug, is one of the several prescription drugs that has encountered the problem of dispensing errors.

Dispensing errors are often a result of miscommunication, which can include poor hand writing of the prescription and confusion between drugs with similar names.//

It is important for patients with epilepsy not to have an interruption in treatment because it could lead to consequence such as status epilepticus.

Conversely, those patients that do not have epilepsy could be placed at unnecessary risk of adverse events, including serious rash, if they are mistakenly given Lamictal.

The most common dispensing errors have been between Lamisil(R), an antifungal tablet and Lamictal.In these instances, either Lamisil was substituted for Lamictal or Lamictal was substituted for Lamisil.

GlaxoSmithKline announced that it has substantially changed the appearance of container labeling and packaging in an effort to reduce the potential for dispensing errors involving its antiepileptic drug Lamictal(lamotrigene).

As a result, GlaxoSmithKline has worked closely with the Food and Drug Administration(FDA) in an effort to educate pharmacists and physicians about the potential for Lamictal dispensing errors.

The container label change is a part of this effort.These efforts reinforce the importance of clear communication between physicians, phamacists and patients.


Page: 1

Related medicine news :

1. GlaxoSmithKline To Cultivate Non-Smoking Environment
2. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
3. FDA Mislead On Asthma Drug By GlaxoSmithKline
4. GlaxoSmithKline Defends Its Products
5. GlaxoSmithKline launches diabetes and cancer drugs
6. Generic Products Compete With GlaxoSmithKline
7. GlaxoSmithKline Agrees To Settle Paxil Claims For $14 million
8. GlaxoSmithKlines Zofran Helps In Treatment Of Dehydration In Children
9. GlaxoSmithKline’s Epilepsy Drug given the Green Signal by FD
10. GlaxoSmithKline’s Tykerb is to Be Started Earlier in Breast Cancer, Study Find
11. GlaxoSmithKline Signs Outsourcing Deal With TCS
Post Your Comments:

(Date:11/24/2015)... Church, VA (PRWEB) , ... November 24, 2015 , ... ... — 1:30 p.m. – 3:00 p.m. EST, , FDA has long ... regulations. CLIA regulations apply to performing the tests and do not meet the device ...
(Date:11/24/2015)... ... November 24, 2015 , ... The ... waive paid entry and parking fees at several of their most popular properties, ... Great Barrington in support of REI’s Black Friday #OptOutside Campaign. The Trustees encourage ...
(Date:11/24/2015)... ... November 24, 2015 , ... In response to recent news highlighting Oxycodone ... prescription opioids in the United States grew 400 percent between 1999 and 2010, far ... involved in 37 percent of all fatal drug overdoses. (1) , While oxycodone and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cancer patients, survivors, caregivers, family ... a live taping of the next CURE Connections® video series on ... 2015 Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the nation’s leading provider ... pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic is designed to ... The location is scheduled to operate through Dec. 24. , Holiday Pop-Up Clinic , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 24, 2015 ... of the University of Bern ... Nutrition of the Bern University Hospital "Inselspital" are proud ... develop a novel generation artificial pancreas. Combining a fully ... for diabetic patients with the unequalled accuracy of an ...
(Date:11/24/2015)... , November 24, 2015 st  Scientific Assembly ... America (RSNA) taking place in Chicago ... 1122, Hall A. --> st  Scientific Assembly and Annual ... (RSNA) taking place in Chicago on ... A. --> Molecular Dynamics will present its revolutionary whole ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology: